SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Robert Cheng, Thomas Tu, Nicholas Shackel, Geoffrey W McCaughan, Advances in and the future of treatments for hepatitis C, Expert Review of Gastroenterology & Hepatology, 2014, 8, 6, 633

    CrossRef

  2. 2
    Jens M. Kittner, Nora M. Weiss, Jörg Wiltink, Jörg M. Schattenberg, Annette Grambihler, Florian Thieringer, Arndt Weinmann, Tim Zimmermann, Sandra Koch, Marcus Schuchmann, Peter R. Galle, Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents, Digestive and Liver Disease, 2014, 46, 1, 67

    CrossRef

  3. You have free access to this content3
    Mitchell L. Shiffman, Yves Benhamou, HCV F1/F2 patients: treat now or continue to wait, Liver International, 2014, 34,
  4. 4
    Mitchell L. Shiffman, April G. Long, Amy James, Phillip Alexander, My Treatment Approach to Chronic Hepatitis C Virus, Mayo Clinic Proceedings, 2014, 89, 7, 934

    CrossRef

  5. 5
    Dennis J. Cada, Jasen Cong, Danial E. Baker, Sofosbuvir, Hospital Pharmacy, 2014, 49, 5, 466

    CrossRef

  6. 6
    Timothy A. Stammers, René Coulombe, Martin Duplessis, Gulrez Fazal, Alexandre Gagnon, Michel Garneau, Sylvie Goulet, Araz Jakalian, Steven LaPlante, Jean Rancourt, Bounkham Thavonekham, Dominik Wernic, George Kukolj, Pierre L. Beaulieu, Anthranilic acid-based Thumb Pocket 2 HCV NS5B polymerase inhibitors with sub-micromolar potency in the cell-based replicon assay, Bioorganic & Medicinal Chemistry Letters, 2013, 23, 24, 6879

    CrossRef